Panacea Biotec Ltd has come under regulatory review after the National Control of Pharmaceutical and Health Products (NCPHP) proposed halting supplies of non-vital products and cited non-compliance with Good Manufacturing Practices (GMP). However, officials clarified that no risk was observed to the quality of products already released.
Show moreStay Ahead – Explore Now! Aye Finance IPO Launches with Price Band of ₹122–₹129 per Share
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
